Xeljanz receives marketing authorisation in EU to treat active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis Read more
NRx Pharmaceuticals announces positive safety report for Zyesami in NIH-sponsored ACTIV-3 study in COVID-19 patients Read more